Quinupristin/dalfopristin-induced Sweet's syndrome.
Quinupristin/Dalfopristin is a new combination of streptogramin antibiotics designed specifically to treat clinically significant infections due to Vancomycin-resistant Enterococcus Faecium. Sweet's syndrome is characterized by painful skin plaques, which is associated with dermal neutrophilic infiltration, fever and peripheral blood leukocytosis. Drug-induced Sweet's syndrome has a temporal relationship between drug ingestion, clinical presentation and the temporally-related resolution of lesions following drug withdrawal or on treatment with systemic corticosteroids. A 63-year-old woman received Quinupristin/Dalfopristin for acute pyelonephritis developed fever, arthralgia, vomiting, and painful erythematous skin plaques. A skin biopsy showed neutrophilic dermatosis, and there was rapid resolution of the symptoms and cutaneous lesions after discontinuation of Quinupristin/Dalfopristin, consistent with drug-induced Sweet's syndrome. To date, there has been no reported case of Sweet's syndrome associated with the use of Quinupristin/Dalfopristin.
Choi
Hye Sook
HS
Department of Internal Medicine, School of Medicine, Kyung Hee University, Seoul, Korea.
Kim
Hee Jin
HJ
Lee
Tae Hee
TH
Lee
Sang Hoon
SH
Lee
Tae Won
TW
Ihm
Chun Gyoo
CG
Kim
Myung Jae
MJ
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D012867:Skin / Q000187:drug effects / Q000473:pathology; D016463:Sweet Syndrome / Q000139:chemically induced* / Q000473:pathology; D014769:Virginiamycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*
D000900:Anti-Bacterial Agents; D014769:Virginiamycin; C113825:quinupristin; C113826:dalfopristin